港股异动 | 百奥赛图-B(02315)午前涨超5% 中期股东应占溢利4799.9万元公司基因编辑技术价值凸显

智通财经

Sep 03

智通财经APP获悉，百奥赛图-B(02315)午前涨超5%，截至发稿，涨4.83%，报24.76港元，成交额744.04万港元。

消息面上，近日，百奥赛图-B发布截至2025年6月30日止6个月中期业绩，集团收益人民币6.21亿元，同比增长51.3%；股东应占溢利4799.9万元，同比扭亏为盈；每股盈利0.12元。2025年上半年，以创新动物模型销售为核心的临床前产品与服务业务实现营业收入人民币4.58亿元，较去年同期增长56.9%，同时毛利率保持在约70%的高水平。作为公司业绩增长的另一核心驱动力，抗体发现业务2025年上半年实现营业收入人民币1.63亿元，较去年同期增长37.8%，毛利率约90%。

智通财经APP在《中报营收大增51.5%，如何解码百奥赛图-B(02315)业绩背后的稀缺性价值？》中指出，以全球领先的基因编辑技术为基石，百奥赛图成功构建了以创新动物模型和抗体分子转让开发为核心的双引擎增长模式，开创了一条区别于传统CRO与药企的平台型创新biotech之路。值得一提的是，凭借RenMice系列全人抗体小鼠平台、“千鼠万抗”计划及全球化的专利网络，公司已逐步构筑起技术、专利层面的双重护城河，形成了难以复制的竞争壁垒。随着未来百奥赛图加速确立其“全球新药发源地”的行业地位，其长期成长价值和投资吸引力正持续提升。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2564356252"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564356252\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564356252?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-03 11:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564356252","market":"hk","top_or_hot":-1,"title":"港股异动 | 百奥赛图-B(02315)午前涨超5% 中期股东应占溢利4799.9万元 公司基因编辑技术价值凸显","media":"智通财经","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/02315\">百奥赛图-B</a>(02315)午前涨超5%，截至发稿，涨4.83%，报24.76港元，成交额744.04万港元。</p><p>消息面上，近日，百奥赛图-B发布截至2025年6月30日止6个月中期业绩，集团收益人民币6.21亿元，同比增长51.3%；股东应占溢利4799.9万元，同比扭亏为盈；每股盈利0.12元。2025年上半年，以创新动物模型销售为核心的临床前产品与服务业务实现营业收入人民币4.58亿元，较去年同期增长56.9%，同时毛利率保持在约70%的高水平。作为公司业绩增长的另一核心驱动力，抗体发现业务2025年上半年实现营业收入人民币1.63亿元，较去年同期增长37.8%，毛利率约90%。</p><p>智通财经APP在《中报营收大增51.5%，如何解码百奥赛图-B(02315)业绩背后的稀缺性价值？》中指出，以全球领先的基因编辑技术为基石，百奥赛图成功构建了以创新动物模型和抗体分子转让开发为核心的双引擎增长模式，开创了一条区别于传统CRO与药企的平台型创新biotech之路。值得一提的是，凭借RenMice系列全人抗体小鼠平台、“千鼠万抗”计划及全球化的专利网络，公司已逐步构筑起技术、专利层面的双重护城河，形成了难以复制的竞争壁垒。随着未来百奥赛图加速确立其“全球新药发源地”的行业地位，其长期成长价值和投资吸引力正持续提升。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 百奥赛图-B(02315)午前涨超5% 中期股东应占溢利4799.9万元 公司基因编辑技术价值凸显</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 百奥赛图-B(02315)午前涨超5% 中期股东应占溢利4799.9万元 公司基因编辑技术价值凸显\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-03 11:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1340893.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，百奥赛图-B(02315)午前涨超5%，截至发稿，涨4.83%，报24.76港元，成交额744.04万港元。消息面上，近日，百奥赛图-B发布截至2025年6月30日止6个月中期业绩，集团收益人民币6.21亿元，同比增长51.3%；股东应占溢利4799.9万元，同比扭亏为盈；每股盈利0.12元。2025年上半年，以创新动物模型销售为核心的临床前产品与服务业务实现营业收入人民币...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1340893.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1340893.html","article_id":"2564356252","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564356252","pubTimestamp":1756871697,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，百奥赛图-B午前涨超5%，截至发稿，涨4.83%，报24.76港元，成交额744.04万港元。消息面上，近日，百奥赛图-B发布截至2025年6月30日止6个月中期业绩，集团收益人民币6.21亿元，同比增长51.3%；股东应占溢利4799.9万元，同比扭亏为盈；每股盈利0.12元。作为公司业绩增长的另一核心驱动力，抗体发现业务2025年上半年实现营业收入人民币1.63亿元，较去年同期增长37.8%，毛利率约90%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02315":"百奥赛图-B","BK1161":"生物科技"},"translate_title":"Changes in Hong Kong stocks | Biocyto-B (02315) rose more than 5% before noon, mid-term profit attributable to shareholders was 47.999 million yuan, and the value of the company's gene editing technology was highlighted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"智通财经APP获悉，百奥赛图-B(02315)午前涨超5%，截至发稿，涨4.83%，报24.76港元，成交额744.04万港元。消息面上，近日，百奥赛图-B发布截至2025年6月30日止6个月中期业绩，集团收益人民币6.21亿元，同比增长51.3%；股东应占溢利4799.9万元，同比扭亏为盈；每股盈利0.12元。2025年上半年，以创新动物模型销售为核心的临床前产品与服务业务实现营业收入人民币4.58亿元，较去年同期增长56.9%，同时毛利率保持在约70%的高水平。作为公司业绩增长的另一核心驱动力，抗体发现业务2025年上半年实现营业收入人民币1.63亿元，较去年同期增长37.8%，毛利率约90%。智通财经APP在《中报营收大增51.5%，如何解码百奥赛图-B(02315)业绩背后的稀缺性价值？》中指出，以全球领先的基因编辑技术为基石，百奥赛图成功构建了以创新动物模型和抗体分子转让开发为核心的双引擎增长模式，开创了一条区别于传统CRO与药企的平台型创新biotech之路。值得一提的是，凭借RenMice系列全人抗体小鼠平台、“千鼠万抗”计划及全球化的专利网络，公司已逐步构筑起技术、专利层面的双重护城河，形成了难以复制的竞争壁垒。随着未来百奥赛图加速确立其“全球新药发源地”的行业地位，其长期成长价值和投资吸引力正持续提升。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}